Literature DB >> 10837642

Aluminum compounds as vaccine adjuvants.

.   

Abstract

Aluminum compounds are the only adjuvants used widely with routine human vaccines and are the most common adjuvants in veterinary vaccines also. Though there has been a search for alternate adjuvants, aluminum adjuvants will continue to be used for many years due to their good track record of safety, low cost and adjuvanticity with a variety of antigens. For infections that can be prevented by induction of serum antibodies, aluminum adjuvants formulated under optimal conditions are the adjuvants of choice. It is important to select carefully the type of aluminum adjuvant and optimize the conditions of adsorption for every antigen since this process is dependent upon the physico-chemical characteristics of both the antigens and aluminum adjuvants. Adsorption of antigens onto aluminum compounds depends heavily on electrostatic forces between adjuvant and antigen. Two commonly used aluminum adjuvants, aluminum hydroxide and aluminum phosphate have opposite charge at a neutral pH. The mechanism of adjuvanticity of aluminum compounds includes formation of a depot; efficient uptake of aluminum adsorbed antigen particles by antigen presenting cells due their particulate nature and optimal size (<10 µm); and stimulation of immune competent cells of the body through activation of complement, induction of eosinophilia and activation of macrophages. Limitations of aluminum adjuvants include local reactions, augmentation of IgE antibody responses, ineffectiveness for some antigens and inability to augment cell-mediated immune responses, especially cytotoxic T-cell responses.

Entities:  

Year:  1998        PMID: 10837642     DOI: 10.1016/s0169-409x(98)00008-8

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  126 in total

1.  Myth, menace or medical blessing? The clinical potential and the problems of genetic vaccines.

Authors:  W W Leitner
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Immunogenicity of two Echinococcus granulosus antigens EgA31 and EgTrp in mice.

Authors:  M Fraize; M E Sarciron; S Azzouz; N Issaadi; G Bosquet; A F Petavy
Journal:  Parasitol Res       Date:  2005-04-12       Impact factor: 2.289

Review 4.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

5.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

6.  Polymer blend particles with defined compositions for targeting antigen to both class I and II antigen presentation pathways.

Authors:  Kenny K Tran; Xi Zhan; Hong Shen
Journal:  Adv Healthc Mater       Date:  2013-10-02       Impact factor: 9.933

Review 7.  Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines.

Authors:  Shishir Kumar Gupta; Preety Bajwa; Rajib Deb; Madhan Mohan Chellappa; Sohini Dey
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

8.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

9.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

10.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.